Proteins and Peptides

30 July 2013

FDA lifts clinical hold on Cangene’s hemophilia compound IB1001

30 July 2013

Adocia reacquires exclusive development rights to ultra-fast acting insulin analog

29 July 2013

aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines

25 July 2013

Questcor to Commence Phase 2 Study of Acthar for ALS

22 July 2013

European Medicines Agency Approves SmPC Change to Baxter’s ADVATE to Include Information on PK-Guided Dosing Study

19 July 2013

US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review

17 July 2013

Synergy Pharmaceuticals’ Plecanatide Phase 2b Trial in IBS-C Reaches Enrollment Halfway Mark

16 July 2013

FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin™ Gel for the Treatment of Chronic Wounds and Scar Reduction

15 July 2013

Alize Pharma launches the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes

11 July 2013

Biodel Announces Completion of Dosing in Phase 2 Clinical Trial of BIOD-123 in Patients With Type 1 Diabetes

11 July 2013

Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors (“GEP-NETs”)

10 July 2013

Generex Oral-lyn Results in More Rapid Reductions of HbA1c in Shreya’s Phase III Study of Type 2 Diabetes in India

8 July 2013

Oramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial

8 July 2013

Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

8 July 2013

Bayer Initiates Phase III Trial of New Investigational Recombinant Factor VIII Compound in Children with Hemophilia A

6 July 2013

Baxter Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients

4 July 2013

Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE

4 July 2013

ERYTECH Announces Fast Take-off of Its Phase IIb Study in Acute Myeloid Leukemia

3 July 2013

CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers

3 July 2013

CSL Behring Presents Population Pharmacokinetic Model for Novel Recombinant Factor IX Hemophilia B Treatment That Supports Less Frequent Administration

3 July 2013

CSL Behring International Trial Shows Clinical Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) for Once Weekly Prophylaxis in Patients with Severe Hemophilia B

2 July 2013

CSL Behring Announces Results from Study of Recombinant Single-Chain Factor VIII (rVIII-SingleChain) for Treatment of Hemophilia A

2 July 2013

Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX

2 July 2013

Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R)

2 July 2013

The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

2 July 2013

La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-501

2 July 2013

Baxter Reports Results of ADVATE Real-World Experience from Worldwide Post-Marketing Database of Hemophilia A Patients

2 July 2013

New Coagulation Factor VIIa (Recombinant) Shows Dose Response and is Well Tolerated in Patients with Hemophilia A and B (with or without inhibitors).

2 July 2013

Celldex Therapeutics Initiates Pilot Study in Dense Deposit Disease

2 July 2013

Achillion Provides Update on Sovaprevir Development Program

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CCR8-Targeted Antibody Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

CD73 Inhibitor Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

TL1A Inhibitor Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing